OSENI 25/45 25 mg alogliptin (as benzoate) / 45 mg pioglitazone (as hydrochloride) film-coated tablet bottle

Nchi: Australia

Lugha: Kiingereza

Chanzo: Department of Health (Therapeutic Goods Administration)

Viambatanisho vya kazi:

pioglitazone hydrochloride, Quantity: 49.59 mg (Equivalent: pioglitazone, Qty 45 mg); alogliptin benzoate, Quantity: 34 mg (Equivalent: alogliptin, Qty 25 mg)

Inapatikana kutoka:

Takeda Pharmaceuticals Australia Pty Ltd

INN (Jina la Kimataifa):

Alogliptin benzoate,Pioglitazone hydrochloride

Dawa fomu:

Tablet, film coated

Tungo:

Excipient Ingredients: croscarmellose sodium; hyprolose; iron oxide red; lactose monohydrate; purified talc; mannitol; microcrystalline cellulose; magnesium stearate; titanium dioxide; hypromellose; macrogol 8000; Shellac; ethanol absolute; iron oxide black; 1-butanol

Njia ya uendeshaji:

Oral

Vitengo katika mfuko:

90, 100, 14 (sample pack), 30, 56, 28, 7 (sample pack), 10 (sample pack), 60, 98

Dawa ya aina:

(S4) Prescription Only Medicine

Matibabu dalili:

OSENI is indicated to improve glycaemic control in adult patients (> or = 18 years old) with type 2 diabetes mellitus when diet and exercise do not provide adequate glycaemic control and treatment with both alogliptin and pioglitazone is appropriate,- when treatment with metformin or pioglitazone alone does not provide adequate control; or,- in combination with metformin when dual therapy does not provide adequate control.,OSENI can also be used to replace separate tablets of alogliptin and pioglitazone in patients already being treated with this combination.

Bidhaa muhtasari:

Visual Identification: Red, round, biconvex, film-coated tablets with A/P and 25/45 printed on one side; Container Type: Bottle; Container Material: HDPE; Container Life Time: 48 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Child resistant closure

Idhini hali ya:

Licence status A

Idhini ya tarehe:

2015-02-10